| NEURAXPHARM |
NEURAXPHARM |
92%
|
License, milestone, royalty and other revenue consist primarily of recognition of consideration received under the ex-U.S. commercialization agreement (the Commercialization Agreement) with Neuraxpharm. |
| CUSTOMER-1 |
CUSTOMER-1 |
90%
|
Three months ended March 31, 2026 Customer 1 42 % 39 % |
| CUSTOMER-2 |
CUSTOMER-2 |
90%
|
Three months ended March 31, 2026 Customer 2 27 % 34 % |
| CUSTOMER-3 |
CUSTOMER-3 |
90%
|
Three months ended March 31, 2026 Customer 3 20 % 16 % |
| CUSTOMER-4 |
CUSTOMER-4 |
90%
|
Three months ended March 31, 2026 Customer 4 9 % 11 % |
| DTIL |
Precision BioSciences, Inc. |
72%
|
Reciprocal relationship from DTIL graph: Reciprocal relationship from TGTX graph: Reciprocal relationship from DTIL graph: Reciprocal relationship from TGTX graph: Reciprocal relationship from DTIL g… |
| DTIL |
Precision BioSciences, Inc. |
72%
|
oduct candidates. The Company may seek significant additional financing in the future to support strategic initiatives and its ongoing and planned operations. The Company's common stock is quoted on … |
| HTGC |
Hercules Capital, Inc. |
72%
|
nd approximately $ 52.3 million related to restricted stock with market conditions, expected to be recognized over a weighted-average period of 2.9 years. Milestone-based noncash compensation expense… |
| HTGC |
Hercules Capital, Inc. |
72%
|
Reciprocal relationship from HTGC graph: Reciprocal relationship from TGTX graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from TGTX graph: Reciprocal relationship from HTGC g… |
| MXCT |
MaxCyte, Inc. |
72%
|
Reciprocal relationship from MXCT graph: ory approval for all or any product candidates covered by their SPL agreements with us, in which case we will not receive the full potential precommercial mil… |
| NVSEF |
Novartis AG |
72%
|
all rights under the Commercialization Agreement for a period of two years in the event of a change in control of TG. 13 Table of Contents TG-1701 (BTK inhibitor) In January 2018, we entered into… |
| NVSEF |
Novartis AG |
72%
|
Reciprocal relationship from NVSEF graph: Reciprocal relationship from TGTX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from TGTX graph: Reciprocal relationship from NVSE… |
| OBDC |
Blue Owl Capital Corporation |
72%
|
our only marketed product. We expect to continue to incur significant research and development expenses, as well as significant commercialization and outsourced manufacturing expenses as we continue … |
| OBDC |
Blue Owl Capital Corporation |
72%
|
Reciprocal relationship from OBDC graph: Reciprocal relationship from TGTX graph: Reciprocal relationship from OBDC graph: Reciprocal relationship from TGTX graph: Reciprocal relationship from OBDC g… |
| CORNER-POST-INC |
CORNER-POST-INC |
62%
|
y outcome of the clinical study may be met, regulatory agencies may still consider such a product not pharmaceutically equivalent. SubQ formulation may involve higher concentration of the existing IV… |
| PUBLICLY-TRADED-COMPANY |
PUBLICLY-TRADED-COMPANY |
62%
|
and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading, which could have a material adverse eff… |
| TG-CELL-THERAPY-INC |
TG-CELL-THERAPY-INC |
62%
|
0.0 million upon contract execution and a $ 12.5 million milestone payment upon the first key market commercial launch in the EU. The Company is eligible to receive up to an additional $ 492.5 millio… |
